Skip to main content
Clinical Trials/NCT03066843
NCT03066843CompletedNot Applicable

A Randomized Controlled Trial Evaluating 5-aminolevulinic Acid Photodynamic Therapy With Different Incubation Times for the Treatment of Actinic Keratosis

Northwestern University1 site in 1 country28 target enrollmentStarted: March 1, 2017Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
28
Locations
1
Primary Endpoint
Change in number of Actinic Keratosis (AK) lesions

Study Overview

Brief Summary

This is a randomized clinical trial evaluating blue light 5-aminolevulinic acid (ALA) photodynamic therapy with different incubation times for the treatment of actinic keratosis.

Subjects who are interested in participating, currently living in the Chicago metropolitan area, and meet inclusion and exclusion criteria will be enrolled in the study. Subjects will be randomized to either 1) zero time ALA incubation or 2) 1 hour ALA incubation. Demographic and health data will be collected prior to treatment initiation. Three visits will be conducted: screening, treatment, and follow up visit at 8 weeks.

This study is a pilot study designed to determine feasibility of this procedure.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Subjects who have been diagnosed with actinic keratosis.
  • •Subjects who by the investigator deem to be suitable for photodynamic therapy of the face or scalp.
  • •Males or females ≥ 18 years old
  • •Fitzpatrick skin types I-VI
  • •Subjects are in good health as judged by the investigator.
  • •Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator.

Exclusion Criteria

  • •Subjects who by the investigator are not suitable for photodynamic therapy.
  • •Lesions suspicious or proven for skin cancer
  • •History of 2 or more ALA- PDT treatments within the past 6 months.
  • •Use of keratolytics within 2 days of initiation of treatment (e.g., >5% urea, glycolic acid, lactic acid, salicyclic acid)
  • •Cryotherapy within the past 2 weeks.
  • •Topical retinoids within the past 4 weeks
  • •Procedures, such as microdermabrasion, ablative lasers, ALA-PDT, chemical peels, 5-fluorouraci, diclofenac, imiquimod within the past 8 weeks
  • •Systemic retinoids within the past 6 months
  • •Pregnant or breast feeding
  • •Uncooperative subjects or subjects with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.
  • •Subjects who are unable to understand the protocol or give informed consent.
  • •Subjects who in the opinion of the investigator are not suitable for the study.

Arms & Interventions

One hour incubation with ALA (5-aminolevulinic acid)

Experimental

Subjects will receive one hour of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.

Intervention: Blue light therapy (Device)

Zero incubation with ALA (5-aminolevulinic acid)

Experimental

Subjects will receive zero time of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.

Intervention: ALA (5-aminolevulinic acid) (Drug)

Zero incubation with ALA (5-aminolevulinic acid)

Experimental

Subjects will receive zero time of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.

Intervention: Blue light therapy (Device)

One hour incubation with ALA (5-aminolevulinic acid)

Experimental

Subjects will receive one hour of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.

Intervention: ALA (5-aminolevulinic acid) (Drug)

Outcomes

Primary Outcomes

Change in number of Actinic Keratosis (AK) lesions

Time Frame: Baseline and 8 Weeks

The number of AK lesions will be counted by a live, blinded assessor at baseline and at Week 8 follow-up visit.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Murad Alam

Professor in Dermatology, Otolaryngology-Head and Neck Surgery, and Surgery

Northwestern University

Study Sites (1)

Loading locations...

Similar Trials